Healthcare outperforms S&P 500 as large cap pharma rebounds

Trading charts background


  • Healthcare stocks led the gainers in the S&P 500 on Thursday, as large-cap pharma stocks witnessed a resurgence a day after the U.S. Federal Reserve approved its third consecutive interest-rate increase of 0.75 percentage points signaling additional large hikes for the year.
  • While leading drugmakers Merck (MRK), Johnson & Johnson (JNJ) and Amgen (AMGN), and UnitedHealth (UNH) dominated the S&P 500, VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH), representing 25 global pharma stocks, rose after seven straight sessions of losses.
  • Merck (MRK) posted the second-best intraday gain for the year after winning a patent lawsuit against Viatris (VTRS) over its blockbuster diabetes drugs Januvia and Janumet.
  • Meanwhile, Eli Lilly (LLY) recorded the best gain for 2022 after UBS upgraded the stock citing the company’s prospects in the weight loss market and Alzheimer’s space.
  • Read: Seeking Alpha contributor North Post Research cites a positive correlation between healthcare and inflation, which reached a four-decade high in June with a 9.1% rise in the consumer price index.

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.